New shot aims to slash 'Silent' heart risk in 204-Patient trial
Disease control
Recruiting now
This study tests an experimental drug called Kylo-11 in 204 adults with heart disease and high levels of lipoprotein(a), a genetic risk factor that standard treatments often miss. Participants receive either the drug or a placebo as a shot, and researchers track how much Lp(a) dr…
Phase: PHASE2 • Sponsor: Kylonova (Xiamen) Biopharma co., LTD. • Aim: Disease control
Last updated May 17, 2026 11:16 UTC